Aspirin and mortality in patients treated with angiotensin-converting enzyme inhibitors - A cohort study of 11,575 patients with coronary artery disease

被引:65
作者
Leor, J
Reicher-Reiss, H
Goldbourt, U
Boyko, V
Gottlieb, S
Battler, A
Behar, S
机构
[1] Ben Gurion Univ Negev, Dept Cardiol, Soroka Med Ctr, Fac Hlth Sci, IL-84105 Beer Sheva, Israel
[2] Tel Aviv Univ, Neufeld Cardiac Res Inst, Tel Hashomer, Israel
关键词
D O I
10.1016/S0735-1097(99)00129-1
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE The purpose of this study was to investigate the significance of the possible negative interaction between aspirin and angiotensin-converting enzyme (ACE) inhibitors. BACKGROUND Several provocative reports have recently suggested that aspirin is unsafe in patients with heart failure and has negative interaction with ACE inhibitors that might attenuate their beneficial effects upon survival. METHODS We analyzed mortality data of 11,575 patients with coronary artery disease screened for the Bezafibrate Infarction Prevention trial. A total of 1,247 patients (11%) were treated with ACE inhibitors. Of them, 618 patients (50%) used aspirin. RESULTS Five-year mortality was lower among patients on ACE inhibitors and aspirin than patients on ACE inhibitors without aspirin (19% vs. 27%; p < 0.001). After adjusting for confounders, treatment with aspirin and ACE inhibitors remained associated with lower mortality risk than using ACE inhibitors only (relative risk [RR] = 0.71; 95% confidence interval [CI] = 0.56 to 0.91). Subgroup analysis of 464 patients with congestive heart failure treated with ACE inhibitors revealed 221 patients (48%) on aspirin and 243 patients not on aspirin. Although clinical characteristics and therapy were similar, patients taking aspirin experienced lower mortality than patients who did not (24% vs. 34%; p 0.001). After adjustment, treatment with aspirin was still associated with lower mortality (RR = 0.70; 95% CI = 0.49 to 0.99). CONCLUSIONS Among coronary artery disease patients with and without heart failure who are treated with ACE inhibitors, the use of aspirin was associated with lower mortality than treatment without aspirin. Our findings contradict the claim that aspirin attenuates the beneficial effect of ACE inhibitors and supports its use in patients with coronary artery disease treated with ACE inhibitors. (C) 1999 by the American College of Cardiology.
引用
收藏
页码:1920 / 1925
页数:6
相关论文
共 25 条
[1]   Antiplatelet agents and survival: A cohort analysis from the studies of left ventricular dysfunction (SOLVD) trial [J].
Al-Khadra, AS ;
Salem, DN ;
Rand, WM ;
Udelson, JE ;
Smith, JJ ;
Konstam, MA .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1998, 31 (02) :419-425
[2]   ASPIRIN ENHANCES THE BENEFITS OF LATE REPERFUSION ON INFARCT SHAPE - A POSSIBLE MECHANISM OF THE BENEFICIAL-EFFECTS OF ASPIRIN ON SURVIVAL AFTER ACUTE MYOCARDIAL-INFARCTION [J].
ALHADDAD, IA ;
TKACZEVSKI, L ;
SIDDIQUI, F ;
MIR, R ;
BROWN, EJ .
CIRCULATION, 1995, 91 (11) :2819-2823
[3]   COLLABORATIVE OVERVIEW OF RANDOMIZED TRIALS OF ANTIPLATELET THERAPY .1. PREVENTION OF DEATH, MYOCARDIAL-INFARCTION, AND STROKE BY PROLONGED ANTIPLATELET THERAPY IN VARIOUS CATEGORIES OF PATIENTS [J].
ALTMAN, R ;
CARRERAS, L ;
DIAZ, R ;
FIGUEROA, E ;
PAOLASSO, E ;
PARODI, JC ;
CADE, JF ;
DONNAN, G ;
EADIE, MJ ;
GAVAGHAN, TP ;
OSULLIVAN, EF ;
PARKIN, D ;
RENNY, JTG ;
SILAGY, C ;
VINAZZER, H ;
ZEKERT, F ;
ADRIAENSEN, H ;
BERTRANDHARDY, JM ;
BRAN, M ;
DAVID, JL ;
DRICOT, J ;
LAVENNEPARDONGE, E ;
LIMET, R ;
LOWENTHAL, A ;
MORIAU, M ;
SCHAPIRA, S ;
SMETS, P ;
SYMOENS, J ;
VERHAEGHE, R ;
VERSTRAETE, M ;
ATALLAH, A ;
BARNETT, H ;
BATISTA, R ;
BLAKELY, J ;
CAIRNS, JA ;
COTE, R ;
CROUCH, J ;
EVANS, G ;
FINDLAY, JM ;
GENT, M ;
LANGLOIS, Y ;
LECLERC, J ;
NORRIS, J ;
PINEO, GF ;
POWERS, PJ ;
ROBERTS, R ;
SCHWARTZ, L ;
SICURELLA, J ;
TAYLOR, W ;
THEROUX, P .
BMJ-BRITISH MEDICAL JOURNAL, 1994, 308 (6921) :81-100
[4]  
BAUR LHB, 1995, BRIT HEART J, V73, P227
[5]  
BHOOLA KD, 1992, PHARMACOL REV, V44, P1
[6]   Effect of captopril on prostacyclin and nitric oxide formation in healthy human subjects: Interaction with low dose acetylsalicylic acid [J].
Boger, RH ;
BodeBoger, SM ;
Kramme, P ;
Tsikas, D ;
Gutzki, FM ;
Frolich, JC .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 42 (06) :721-727
[7]   Calcium antagonists and mortality in patients with coronary artery disease: A cohort study of 11,575 patients [J].
Braun, S ;
Boyko, V ;
Behar, S ;
ReicherReiss, H ;
Shotan, A ;
Schlesinger, Z ;
Rosenfeld, T ;
Palant, A ;
Friedensohn, A ;
Laniado, S ;
Goldbourt, U .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1996, 28 (01) :7-11
[8]  
CLELAND JGF, 1995, BRIT HEART J, V74, P215
[9]  
COX DR, 1972, J R STAT SOC B, V34, P187
[10]   PROSTAGLANDINS IN SEVERE CONGESTIVE HEART-FAILURE - RELATION TO ACTIVATION OF THE RENIN-ANGIOTENSIN SYSTEM AND HYPONATREMIA [J].
DZAU, VJ ;
PACKER, M ;
LILLY, LS ;
SWARTZ, SL ;
HOLLENBERG, NK ;
WILLIAMS, GH .
NEW ENGLAND JOURNAL OF MEDICINE, 1984, 310 (06) :347-352